Clinical Trials

Idiopathic Pulmonary Fibrosis Clinical Trials

Specialists at University Hospitals Cleveland Medical Center are happy to participate in idiopathic pulmonary fibrosis clinical research and are currently enrolling patients in these clinical trials:

• A Phase III Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate the Efficacy and Safety of PRM-151 (Recombinant Human Pentraxin-2) in Patients with Idiopathic Pulmonary Fibrosis
• A Phase III Open-Label Extension Study to Evaluate Long-Term Safety & Efficacy of PRM-151(Recombinant Human Pentraxin-2) in Patients with Idiopathic Pulmonary Fibrosis
• A Phase II Multicenter, Multinational Randomized Double-Blind Placebo-Controlled Study Investigating the Safety and Efficacy of Drug CC-90001 at Two Doses 200 and 400 mg per Day in Subjects with IPF